- Home
- MVBF vs VNDA Comparison
MVBF vs VNDA Comparison
Compare MVBF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVBF
- VNDA
- Stock Information
- Founded
- MVBF 1997
- VNDA 2002
- Country
- MVBF United States
- VNDA United States
- Employees
- MVBF N/A
- VNDA N/A
- Industry
- MVBF Major Banks
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MVBF Finance
- VNDA Health Care
- Exchange
- MVBF Nasdaq
- VNDA Nasdaq
- Market Cap
- MVBF 205.7M
- VNDA 237.9M
- IPO Year
- MVBF N/A
- VNDA 2006
- Fundamental
- Price
- MVBF $17.94
- VNDA $3.95
- Analyst Decision
- MVBF Buy
- VNDA Strong Buy
- Analyst Count
- MVBF 3
- VNDA 2
- Target Price
- MVBF $24.67
- VNDA $16.50
- AVG Volume (30 Days)
- MVBF 23.2K
- VNDA 471.1K
- Earning Date
- MVBF 04-30-2025
- VNDA 05-07-2025
- Dividend Yield
- MVBF 3.79%
- VNDA N/A
- EPS Growth
- MVBF N/A
- VNDA N/A
- EPS
- MVBF 1.46
- VNDA N/A
- Revenue
- MVBF $146,101,000.00
- VNDA $201,351,000.00
- Revenue This Year
- MVBF N/A
- VNDA $14.36
- Revenue Next Year
- MVBF $14.09
- VNDA $44.53
- P/E Ratio
- MVBF $12.30
- VNDA N/A
- Revenue Growth
- MVBF N/A
- VNDA 13.37
- 52 Week Low
- MVBF $15.59
- VNDA $3.85
- 52 Week High
- MVBF $25.24
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- MVBF 63.58
- VNDA 33.16
- Support Level
- MVBF $17.13
- VNDA $4.20
- Resistance Level
- MVBF $18.20
- VNDA $4.51
- Average True Range (ATR)
- MVBF 0.68
- VNDA 0.18
- MACD
- MVBF 0.18
- VNDA -0.02
- Stochastic Oscillator
- MVBF 88.05
- VNDA 1.43
About MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.